AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

NCT05247684 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Resectable Non-small Cell Lung Cancer

Interventions

DRUG: AK112
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Paclitaxel

Sponsor

Akeso